Histologic or cytologic diagnosis of stage IIIB/IV NSCLC 
ECOG PS: 0,1 
Unidimensional or bi-dimensional measurable disease 
Receive prior treatment including first-line platinum-based chemotherapy, standard second-line chemotherapy and 1 EGF/EGFR inhibitor 
Evidence of disease progression 
Life expectancy >12 weeks 
Neutrophils > 1.5 109/l, Platelets > 100 109/l, Hemoglobin > 9g/dl, Total bilirubin < 1.5 UNL, AST (SGOT) and ALT (SGPT) < 2.5 UNL, Alkaline phosphatases < 5 UNL, Creatinine < 1 UNL 

NCT01850147_inc_T1
Procedure
Histologic
NCT01850147_inc_T2
Procedure
cytologic
NCT01850147_inc_T3
Condition
NSCLC
NCT01850147_inc_T4
Qualifier
stage IIIB/IV
NCT01850147_inc_T5
Measurement
ECOG PS
NCT01850147_inc_T6
Value
0,1
NCT01850147_inc_T8
Qualifier
measurable
NCT01850147_inc_T11
Procedure
treatment
NCT01850147_inc_T12
Procedure
platinum-based chemotherapy
NCT01850147_inc_T13
Procedure
second-line chemotherapy
NCT01850147_inc_T14
Drug
1 EGF/EGFR inhibitor
NCT01850147_inc_T15
Qualifier
standard
NCT01850147_inc_T16
Scope
platinum-based chemotherapy, standard second-line chemotherapy and 1 EGF/EGFR inhibitor
NCT01850147_inc_T17
Condition
disease progression
NCT01850147_inc_T18
Observation
Evidence
NCT01850147_inc_T21
Observation
Life expectancy
NCT01850147_inc_T22
Value
>12 weeks
NCT01850147_inc_T23
Measurement
Neutrophils
NCT01850147_inc_T24
Value
> 1.5 109/l
NCT01850147_inc_T25
Measurement
Platelets
NCT01850147_inc_T26
Value
> 100 109/l
NCT01850147_inc_T27
Measurement
Hemoglobin
NCT01850147_inc_T28
Value
> 9g/dl
NCT01850147_inc_T29
Measurement
Total bilirubin
NCT01850147_inc_T30
Value
< 1.5 UNL
NCT01850147_inc_T31
Measurement
ALT (SGPT)
NCT01850147_inc_T32
Value
< 2.5 UNL
NCT01850147_inc_T33
Measurement
AST (SGOT)
NCT01850147_inc_T34
Measurement
Alkaline phosphatases
NCT01850147_inc_T35
Value
< 5 UNL
NCT01850147_inc_T36
Measurement
Creatinine
NCT01850147_inc_T37
Value
< 1 UNL